

Buy EUR 192.00	(EUR 200.00)	Value Indicators: DCF:		Warburg ESG Risk Score: ESG Score (MSCI based): Balance Sheet Score: Market Liquidity Score:	3.0 3.0 5.0 1.0	Description: ATOSS supplies software and services for the optimisation of workforce management.		
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2022e	
		Market cap:	935.3	Freefloat	44.20 %	Beta:	1.0	
Price	EUR 117.60	No. of shares (m):	8.0	Andreas Obereder	50.00 %	Price / Book:	21.2 x	
Upside	63.3 %	EV:	885.8	Mainfirst	5.80 %	Equity Ratio:	51 %	
	30.0 /0	Freefloat MC:	413.4					
		Ø Trad. Vol. (30d):	454.57 th					

Still running like clockwork

Stated Figures Q	3/2022:						
Figures in EUR m	Q3/22	Q3/22e	Q3/21	yoy	9M/22	9M/21	yoy
Sales	28.3	28.0	23.8	18.8%	81.9	69.5	17.8%
EBIT	7.8	7.4	6.6	17.8%	21.6	18.6	16.4%
margin	27.4%	26.4%	27.7%		26.4%	26.7%	
Net income	5.5	5.3	4.4	23.5%	13.7	12.7	8.5%
margin	19.3%	18.9%	18.6%		16.8%	18.2%	

The 2022 financial year is likely to show a one-off stagnation in earnings due to the steady conversion of the business model to cloud-based billing and the associated typical shift in billing (from advance licenses to rental payments, but with a higher customer lifetime value). FY 2022 will also be burdened by a lower financial result. From 2023 onwards, the increasing share of the cloud business and a high number of contracts will ensure a steady increase in margins. In Q3, cloud subscriptions were the largest source of revenue for the first time. In Cloud & Subscriptions, sales rose by 75% to EUR 24.0m (previous year: EUR 13.8m).


The order situation remains positive too. The normalized order intake for software licenses increased by 43% in the first three quarters, rising to a total of EUR 36.6m (EUR 25.6m). Cloud & Subscriptions accounted for EUR 26.6m (previous year: EUR 18.2m) or 73% of all software orders received, which again underlines the success of the cloud transition.

The basis for our assumptions (WRe) remains an EBIT margin increase to 30.5% in 2025 and a terminal margin of 50%. Due to the general economic situation in Europe, the sales and earnings forecasts (WRe) for 2023 and beyond are reduced slightly. Overall, this results in a slight reduction in the price target from EUR 200 to EUR 192. **The stock continues to be rated Buy.**

Changes in E	Estimates:					
FY End: 31.12. in EUR m	2022e (old)	+/-	2023e (old)	+/-	2024e (old)	+/-
Sales	111.5	0.4 %	130.5	-1.3 %	152.6	-3.0 %
EBITDA	34.0	1.1 %	42.8	-1.3 %	50.8	-3.0 %
EBIT	29.1	1.2 %	37.0	-1.3 %	44.1	-3.0 %
EPS	2.43	-1.6 %	3.14	-1.0 %	3.73	-2.7 %
DPS	1.83	-1.6 %	2.36	-1.3 %	2.80	-2.9 %

Comment on Changes:

- Based on the good Q3 figures, there is a slight increase in the EBIT forecasts for 2022.
- Due to a weaker financial result than expected (as already indicated in Q2), this improvement does not fully impact the net result.
- Due to the general economic situation, the forecasts for 2023 and the years thereafter are reduced slightly.




Rel. Performance vs CDAX:	
1 month:	2.4 %
6 months:	-12.8 %
Year to date:	-19.1 %
Trailing 12 months:	-10.0 %

Company	events:	

+49 40 309537-120

FY End: 31.12.	CAGR							
in EUR m	(21-24e)	2018	2019	2020	2021	2022e	2023e	2024e
Sales	15.1 %	62.6	71.4	86.1	97.1	112.0	128.8	148.1
Change Sales yoy		14.7 %	14.0 %	20.5 %	12.8 %	15.4 %	15.0 %	15.0 %
Gross profit margin		70.5 %	70.3 %	72.4 %	73.0 %	69.5 %	71.0 %	71.0 %
EBITDA	16.3 %	18.0	22.5	29.8	31.4	34.4	42.2	49.3
Margin		28.7 %	31.5 %	34.6 %	32.3 %	30.7 %	32.8 %	33.3 %
EBIT	16.3 %	16.9	19.3	26.2	27.2	29.5	36.6	42.8
Margin		27.0 %	27.0 %	30.4 %	28.1 %	26.3 %	28.4 %	28.9 %
Net income	14.3 %	11.2	13.5	17.7	19.3	19.0	24.7	28.9
EPS	14.3 %	1.41	1.70	2.23	2.43	2.39	3.11	3.63
EPS adj.	14.3 %	1.41	1.70	2.23	2.43	2.39	3.11	3.63
DPS	14.3 %	2.01	1.28	1.67	1.82	1.80	2.33	2.72
Dividend Yield		4.8 %	2.2 %	1.6 %	1.0 %	1.5 %	2.0 %	2.3 %
FCFPS		1.37	1.82	2.82	3.17	2.67	3.13	3.75
FCF / Market cap		3.3 %	3.1 %	2.7 %	1.7 %	2.3 %	2.7 %	3.2 %
EV / Sales		4.9 x	6.3 x	9.2 x	14.5 x	7.9 x	6.8 x	5.8 x
EV / EBITDA		17.0 x	19.9 x	26.6 x	44.8 x	25.8 x	20.7 x	17.5 x
EV / EBIT		18.1 x	23.2 x	30.2 x	51.6 x	30.1 x	23.9 x	20.2 x
P/E		29.8 x	34.8 x	46.6 x	74.9 x	49.2 x	37.8 x	32.4 x
P / E adj.		29.8 x	34.8 x	46.6 x	74.9 x	49.2 x	37.8 x	32.4 x
FCF Potential Yield		3.9 %	3.5 %	2.6 %	1.6 %	2.8 %	3.4 %	4.0 %
Net Debt		-28.5	-23.1	-34.3	-42.7	-49.5	-60.0	-71.3
ROCE (NOPAT)		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Guidance:	Sales 2022 El	JR 110+ m E	BIT at least 2	25%				






Company Background

- ATOSS Software AG is a supplier of software and services for the optimisation of workforce management.
- •ATOSS solutions optimises companies' personnel procedures, improving the level of service and efficiency of the employees and improving customer satisfaction
- The company has achieved a leading market position, particularly in the German speaking countries.
- From medium-sized companies (Mittelstand) to blue-chip firms, several million employees use ATOSS solutions.

Competitive Quality

- ATOSS has a leading software product (the most modern Java technology)
- ATOSS specialises in regions and industry sectors (country-specific work conditions in the Germany, Austria, Swiss region and mapping out work processes in core industries)
- ATOSS works independently of producers (no ties to hardware or large software producers) and the ATOSS solutions have a high level of compatibility (e.g. seamless integration in the ERP systems possible)
- Financial stability and balance sheet quality is excellent, which can be regarded as a competitive advantage in the software industry.
- ATOSS is a relatively large supplier (in comparison to the competition) among many much smaller suppliers, which still pose stiff competition for ATOSS.





DCF model														
	Detaile	d forecas	t period				٦	Γransition	al period					Term. Value
Figures in EUR m	2022e	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	
Sales	112.0	128.8	148.1	170.3	195.9	225.3	256.8	290.2	325.0	360.8	389.6	409.1	421.4	
Sales change	15.4 %	15.0 %	15.0 %	15.0 %	15.0 %	15.0 %	14.0 %	13.0 %	12.0 %	11.0 %	8.0 %	5.0 %	3.0 %	2.5 %
EBIT	29.5	36.6	42.8	52.0	65.6	83.4	102.7	124.8	149.5	176.8	194.8	204.6	210.7	
EBIT-margin	26.3 %	28.4 %	28.9 %	30.5 %	33.5 %	37.0 %	40.0 %	43.0 %	46.0 %	49.0 %	50.0 %	50.0 %	50.0 %	
Tax rate (EBT)	33.0 %	33.0 %	33.0 %	34.0 %	34.0 %	34.0 %	34.0 %	34.0 %	34.0 %	34.0 %	34.0 %	34.0 %	34.0 %	
NOPAT	19.7	24.5	28.7	34.3	43.3	55.0	67.8	82.4	98.7	116.7	128.6	135.0	139.1	
Depreciation	4.9	5.7	6.5	7.7	8.8	10.1	11.6	13.1	14.6	16.2	17.5	18.4	19.0	
in % of Sales	4.4 %	4.4 %	4.4 %	4.5 %	4.5 %	4.5 %	4.5 %	4.5 %	4.5 %	4.5 %	4.5 %	4.5 %	4.5 %	
Changes in provisions	0.0	0.0	0.0	0.5	0.5	0.7	0.7	0.6	0.6	0.4	0.5	0.2	-0.1	
Change in Liquidity from														
- Working Capital	-1.3	1.5	1.6	1.4	1.5	1.7	1.6	1.6	1.5	1.3	0.7	0.0	-3.0	
- Capex	4.0	4.0	4.0	7.7	8.8	10.1	11.6	13.1	14.6	16.2	17.5	18.4	19.0	
Capex in % of Sales	3.6 %	3.1 %	2.7 %	4.5 %	4.5 %	4.5 %	4.5 %	4.5 %	4.5 %	4.5 %	4.5 %	4.5 %	4.5 %	
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	22.0	24.7	29.6	33.4	42.3	54.1	66.9	81.4	97.7	115.8	128.4	135.2	142.0	143
PV of FCF	21.8	22.6	25.1	26.2	30.6	36.2	41.3	46.4	51.5	56.4	57.7	56.2	54.5	956
share of PVs		4.69 %						30.82	2 %					64.49 %

Model parameter				Valuation (m)			
Derivation of WACC:		Derivation of Beta:		Present values 2034e	526		
				Terminal Value	956		
Debt ratio	0.00 %	Financial Strength	1.00	Financial liabilities	0		
Cost of debt (after tax)	3.9 %	Liquidity (share)	1.00	Pension liabilities	7		
Market return	8.25 %	Cyclicality	1.00	Hybrid capital	0		
Risk free rate	2.75 %	Transparency	1.00	Minority interest	0		
		Others	1.00	Market val. of investments	0		
				Liquidity	50	No. of shares (m)	8.0
WACC	8.25 %	Beta	1.00	Equity Value	1,525	Value per share (EUR)	191.79

Sens	itivity Va	lue per Sh	are (EUR)													
	Terminal Growth Delta EBIT-margin																
Beta	WACC	1.75 %	2.00 %	2.25 %	2.50 %	2.75 %	3.00 %	3.25 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.18	9.3 %	149.79	152.63	155.68	158.95	162.47	166.28	170.40	1.18	9.3 %	153.91	155.59	157.27	158.95	160.63	162.31	163.99
1.09	8.8 %	162.79	166.25	169.98	174.00	178.36	183.10	188.27	1.09	8.8 %	168.51	170.34	172.17	174.00	175.83	177.66	179.50
1.05	8.5 %	170.06	173.89	178.03	182.51	187.38	192.70	198.52	1.05	8.5 %	176.76	178.68	180.59	182.51	184.43	186.34	188.26
1.00	8.3 %	177.92	182.17	186.78	191.79	197.25	203.24	209.82	1.00	8.3 %	185.76	187.77	189.78	191.79	193.80	195.81	197.82
0.95	8.0 %	186.43	191.17	196.32	201.94	208.10	214.87	222.35	0.95	8.0 %	195.60	197.71	199.83	201.94	204.05	206.17	208.28
0.91	7.8 %	195.69	200.99	206.77	213.09	220.06	227.75	236.30	0.91	7.8 %	206.42	208.64	210.87	213.09	215.32	217.55	219.77
0.82	7.3 %	216.84	223.53	230.90	239.04	248.08	258.19	269.56	0.82	7.3 %	231.58	234.07	236.55	239.04	241.52	244.01	246.50

- In the DCF model, a moderate continuation of the constant growth of the past years is anticipated.
- In the long term, a margin improvement due to the cloud transformation is assumed.
- The long-term margin remains at a high level

ATOSS




Valuation							
	2018	2019	2020	2021	2022e	2023e	2024e
Price / Book	11.7 x	18.9 x	25.5 x	36.7 x	21.2 x	17.2 x	14.4 x
Book value per share ex intangibles	3.54	1.71	2.82	3.46	4.05	5.41	6.74
EV / Sales	4.9 x	6.3 x	9.2 x	14.5 x	7.9 x	6.8 x	5.8 x
EV / EBITDA	17.0 x	19.9 x	26.6 x	44.8 x	25.8 x	20.7 x	17.5 x
EV / EBIT	18.1 x	23.2 x	30.2 x	51.6 x	30.1 x	23.9 x	20.2 x
EV / EBIT adj.*	18.1 x	23.2 x	30.2 x	51.6 x	30.1 x	23.9 x	20.2 x
P / FCF	30.7 x	32.5 x	36.8 x	57.4 x	44.0 x	37.6 x	31.4 x
P/E	29.8 x	34.8 x	46.6 x	74.9 x	49.2 x	37.8 x	32.4 x
P / E adj.*	29.8 x	34.8 x	46.6 x	74.9 x	49.2 x	37.8 x	32.4 x
Dividend Yield	4.8 %	2.2 %	1.6 %	1.0 %	1.5 %	2.0 %	2.3 %
FCF Potential Yield (on market EV)	3.9 %	3.5 %	2.6 %	1.6 %	2.8 %	3.4 %	4.0 %
*Adjustments made for: -							



Consolidated profit and loss							
In EUR m	2018	2019	2020	2021	2022e	2023e	2024
Sales	62.6	71.4	86.1	97.1	112.0	128.8	148.1
Change Sales yoy	14.7 %	14.0 %	20.5 %	12.8 %	15.4 %	15.0 %	15.0 %
COGS	18.4	21.2	23.8	26.2	34.2	37.4	43.0
Gross profit	44.2	50.2	62.3	70.8	77.8	91.4	105.2
Gross margin	70.5 %	70.3 %	72.4 %	73.0 %	69.5 %	71.0 %	71.0 %
Research and development	11.2	11.9	14.4	16.9	19.0	21.9	25.2
Sales and marketing	10.9	12.9	13.9	18.2	19.7	21.9	24.4
Administration expenses	5.2	5.8	7.6	8.3	10.1	11.6	13.3
Other operating expenses	0.2	0.5	0.4	0.4	0.0	0.0	0.0
Other operating income	0.3	0.3	0.2	0.1	0.4	0.5	0.6
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	18.0	22.5	29.8	31.4	34.4	42.2	49.3
Margin	28.7 %	31.5 %	34.6 %	32.3 %	30.7 %	32.8 %	33.3 %
Depreciation of fixed assets	0.9	3.0	3.2	3.6	4.7	5.4	6.2
EBITA	17.1	19.5	26.5	27.8	29.7	36.8	43.1
Amortisation of intangible assets	0.2	0.2	0.3	0.5	0.2	0.3	0.3
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	16.9	19.3	26.2	27.2	29.5	36.6	42.8
Margin	27.0 %	27.0 %	30.4 %	28.1 %	26.3 %	28.4 %	28.9 %
EBIT adj.	16.9	19.3	26.2	27.2	29.5	36.6	42.8
Interest income	0.1	0.8	0.4	0.6	0.0	0.5	0.5
Interest expenses	0.2	0.2	0.4	0.2	1.1	0.2	0.2
Other financial income (loss)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBT	16.8	19.9	26.2	27.7	28.4	36.9	43.1
Margin	26.8 %	27.9 %	30.4 %	28.5 %	25.3 %	28.6 %	29.1 %
Total taxes	5.6	6.4	8.5	8.4	9.4	12.2	14.2
Net income from continuing operations	11.2	13.5	17.7	19.3	19.0	24.7	28.9
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	11.2	13.5	17.7	19.3	19.0	24.7	28.9
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	11.2	13.5	17.7	19.3	19.0	24.7	28.9
Margin	17.9 %	18.9 %	20.6 %	19.9 %	17.0 %	19.2 %	19.5 %
Number of shares, average	8.0	8.0	8.0	8.0	8.0	8.0	8.0
EPS	1.41	1.70	2.23	2.43	2.39	3.11	3.63
EPS adj.	1.41	1.70	2.23	2.43	2.39	3.11	3.63
*Adjustments made for:							

Guidance: Sales 2022 EUR 110+ m EBIT at least 25%


Financial Ratios							
	2018	2019	2020	2021	2022e	2023e	2024e
Total Operating Costs / Sales	43.5 %	43.2 %	42.0 %	44.9 %	43.2 %	42.6 %	42.1 %
Operating Leverage	1.3 x	1.0 x	1.7 x	0.3 x	0.5 x	1.6 x	1.1 x
EBITDA / Interest expenses	72.1 x	100.5 x	75.9 x	192.3 x	31.3 x	211.2 x	246.6 x
Tax rate (EBT)	33.3 %	32.1 %	32.4 %	30.2 %	33.0 %	33.0 %	33.0 %
Dividend Payout Ratio	142.8 %	75.0 %	75.0 %	74.8 %	75.4 %	75.0 %	74.9 %
Sales per Employee	175,832	190,943	219,198	235,477	258,768	283,412	310,404





Consolidated balance sheet							
In EUR m	2018	2019	2020	2021	2022e	2023e	2024e
Assets							
Goodwill and other intangible assets	0.4	11.2	10.0	12.0	11.8	11.5	11.2
thereof other intangible assets	0.4	11.2	10.0	12.0	11.8	11.5	11.2
thereof Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Property, plant and equipment	4.3	4.1	3.8	3.3	2.6	1.2	-1.1
Financial assets	0.5	1.3	1.3	1.3	1.3	1.3	1.3
Other long-term assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fixed assets	5.2	16.6	15.0	16.6	15.7	14.0	11.5
Inventories	0.0	0.0	0.0	0.0	0.1	0.1	0.1
Accounts receivable	6.3	7.7	8.9	11.9	10.7	12.4	14.2
Liquid assets	33.3	29.7	41.1	49.6	56.4	66.9	78.2
Other short-term assets	2.4	4.1	3.0	3.3	3.3	3.5	3.7
Current assets	42.0	41.6	53.0	64.9	70.5	82.9	96.2
Total Assets	47.2	58.1	68.0	81.5	86.2	97.0	107.7
Liabilities and shareholders' equity							
Subscribed capital	4.0	4.0	8.0	8.0	8.0	8.0	8.0
Capital reserve	-0.7	-0.7	-0.7	-0.3	-0.3	-0.3	-0.3
Retained earnings	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other equity components	25.2	21.5	25.1	31.8	36.4	46.9	57.2
Shareholders' equity	28.5	24.8	32.4	39.5	44.0	54.5	64.9
Minority interest	0.0	0.1	-0.1	-0.1	-0.1	-0.1	-0.1
Total equity	28.5	24.9	32.3	39.4	43.9	54.4	64.8
Provisions	4.9	7.3	8.6	7.1	7.2	7.3	7.4
thereof provisions for pensions and similar obligations	4.8	6.6	6.8	6.9	6.9	6.9	6.9
Financial liabilities (total)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Short-term financial liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts payable	0.5	0.9	0.5	1.0	1.2	1.4	1.6
Other liabilities	13.3	25.1	26.6	33.9	33.9	33.9	33.9
Liabilities	18.7	33.3	35.7	42.1	42.3	42.6	42.9
Total liabilities and shareholders' equity	47.2	58.1	68.0	81.5	86.2	97.0	107.7


Financial Ratios							
	2018	2019	2020	2021	2022e	2023e	2024e
Efficiency of Capital Employment							
Operating Assets Turnover	6.2 x	6.6 x	7.1 x	6.8 x	9.2 x	10.5 x	12.7 x
Capital Employed Turnover	-1024.3 x	39.7 x	-43.7 x	-29.4 x	-20.2 x	-23.0 x	-22.7 x
ROA	216.2 %	81.5 %	117.8 %	116.4 %	121.1 %	176.3 %	251.2 %
Return on Capital							
ROCE (NOPAT)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
ROE	44.4 %	50.7 %	61.9 %	53.8 %	45.5 %	50.1 %	48.4 %
Adj. ROE	44.4 %	50.7 %	61.9 %	53.8 %	45.5 %	50.1 %	48.4 %
Balance sheet quality							
Net Debt	-28.5	-23.1	-34.3	-42.7	-49.5	-60.0	-71.3
Net Financial Debt	-33.3	-29.7	-41.1	-49.6	-56.4	-66.9	-78.2
Net Gearing	-100.2 %	-92.8 %	-106.1 %	-108.4 %	-112.6 %	-110.3 %	-110.1 %
Net Fin. Debt / EBITDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Book Value / Share	3.6	3.1	4.1	5.0	5.5	6.9	8.2
Book value per share ex intangibles	3.5	1.7	2.8	3.5	4.1	5.4	6.7





Consolidated cash flow statement							
In EUR m	2018	2019	2020	2021	2022e	2023e	2024e
Net income	11.2	13.5	17.7	19.3	19.0	24.7	28.9
Depreciation of fixed assets	0.9	3.0	3.2	3.6	4.7	5.4	6.2
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	0.2	0.2	0.3	0.5	0.2	0.3	0.3
Increase/decrease in long-term provisions	0.0	1.9	0.2	0.1	0.0	0.0	0.0
Other non-cash income and expenses	1.5	-2.2	3.2	5.4	0.0	0.0	0.0
Cash Flow before NWC change	13.7	16.4	24.7	28.9	23.9	30.4	35.4
Increase / decrease in inventory	0.0	0.0	0.0	0.0	-0.1	0.0	0.0
Increase / decrease in accounts receivable	-1.2	-1.5	-1.1	-3.1	1.2	-1.7	-1.8
Increase / decrease in accounts payable	0.1	0.4	-0.4	0.5	0.2	0.2	0.2
Increase / decrease in other working capital positions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase / decrease in working capital (total)	-1.1	-1.1	-1.5	-2.6	1.3	-1.5	-1.6
Net cash provided by operating activities [1]	12.6	15.3	23.2	26.3	25.2	28.9	33.8
Investments in intangible assets	-0.2	0.0	0.0	0.0	0.0	0.0	0.0
Investments in property, plant and equipment	-1.5	-0.9	-0.7	-1.1	-4.0	-4.0	-4.0
Payments for acquisitions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	0.0	0.0	-3.9	-14.7	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	0.0	2.4	0.0	0.0	0.0
Net cash provided by investing activities [2]	-1.7	-0.9	-4.6	-13.4	-4.0	-4.0	-4.0
Change in financial liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Dividends paid	-4.7	-16.0	-10.1	-13.3	-14.5	-14.3	-18.5
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.0	-2.2	-2.6	- 2.5	0.0	0.0	0.0
Net cash provided by financing activities [3]	-4.7	-18.2	-12.7	-15.8	-14.5	-14.3	-18.5
Change in liquid funds [1]+[2]+[3]	6.2	-3.7	5.9	-2.9	6.8	10.6	11.3
Effects of exchange-rate changes on cash	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash and cash equivalent at end of period	33.4	29.5	23.4	20.5	56.4	66.9	78.2

Financial Ratios							
	2018	2019	2020	2021	2022e	2023e	2024e
Cash Flow							
FCF	10.9	14.4	22.4	25.2	21.2	24.9	29.8
Free Cash Flow / Sales	17.4 %	20.2 %	26.1 %	26.0 %	19.0 %	19.3 %	20.1 %
Free Cash Flow Potential	12.0	15.7	20.8	22.6	24.6	29.6	34.7
Free Cash Flow / Net Profit	97.5 %	106.9 %	126.8 %	130.6 %	111.8 %	100.7 %	103.2 %
Interest Received / Avg. Cash	0.4 %	2.7 %	1.2 %	1.4 %	0.0 %	0.8 %	0.7 %
Interest Paid / Avg. Debt	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Management of Funds							
Investment ratio	2.7 %	1.3 %	0.8 %	1.1 %	3.6 %	3.1 %	2.7 %
Maint. Capex / Sales	0.7 %	0.6 %	0.5 %	0.4 %	0.4 %	0.3 %	0.3 %
Capex / Dep	158.8 %	28.2 %	20.3 %	26.6 %	81.2 %	70.6 %	61.4 %
Avg. Working Capital / Sales	8.3 %	8.8 %	8.8 %	9.9 %	9.2 %	8.0 %	8.0 %
Trade Debtors / Trade Creditors	1226.3 %	840.4 %	1647.0 %	1144.2 %	891.7 %	885.7 %	887.5 %
Inventory Turnover	4131.1 x	4755.4 x	5327.7 x	4319.5 x	341.6 x	373.5 x	429.5 x
Receivables collection period (days)	36	39	38	45	35	35	35
Payables payment period (days)	10	16	8	15	13	14	14
Cash conversion cycle (Days)	26	24	29	30	23	22	22



Source: Warburg Research Source: Warburg Research Source: Warburg Research



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also http://www.mmwarburg.de/disclaimer/disclaimer/htm#Valuation). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

The Warburg ESG Risk Score is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.



Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
- 3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
- 4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
- 5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold -1a share of more than 5% of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the management of a consortium for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- Companies affiliated with Warburg Research manage financial instruments, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide investment banking and/or investment services and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation - provided that this disclosure does not result in the disclosure of confidential business information.
- The company compiling the analysis or an affiliated company had reached an agreement on the compilation of the investment recommendation with the analysed company.
- Warburg Research, or an affiliated company, holds a net long position of more than 0.5% of the total issued share capital of the analysed -6acompany.
- Warburg Research, or an affiliated company, holds a net short position of more than 0.5% of the total issued share capital of the analysed -6bcompany.
- -6c-The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- The company preparing the analysis as well as its affiliated companies and employees have other important interests in relation to the -7analysed company, such as, for example, the exercising of mandates at analysed companies.

This report has been made accessible to the company analysed.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
ATOSS	5	http://www.mmwarburg.com/disclaimer/disclaimer en/DE0005104400.htm



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
<u>"_"</u>	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	162	75
Hold	46	21
Sell	4	2
Rating suspended	4	2
Total	216	100

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	45	80
Hold	8	14
Sell	1	2
Rating suspended	2	4
Total	56	100

PRICE AND RATING HISTORY ATOSS AS OF 24.10.2022



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



EQUITIES			
Matthias Rode Head of Equities	+49 40 3282-2678 mrode@mmwarburg.com		
RESEARCH			
Michael Heider Head of Research	+49 40 309537-280 mheider@warburg-research.com	Thilo Kleibauer Retail, Consumer Goods	+49 40 309537-257 tkleibauer@warburg-research.com
Henner Rüschmeier Head of Research	+49 40 309537-270 hrueschmeier@warburg-research.com	Andreas Pläsier Banks, Financial Services	+49 40 309537-246 aplaesier@warburg-research.com
Stefan Augustin	+49 40 309537-168	Malte Schaumann	+49 40 309537-170
Cap. Goods, Engineering Jan Bauer	saugustin@warburg-research.com +49 40 309537-155	Technology Oliver Schwarz	mschaumann@warburg-research.com +49 40 309537-250
Renewables	jbauer@warburg-research.com	Chemicals, Agriculture	oschwarz@warburg-research.com
Christian Cohrs Industrials & Transportation	+49 40 309537-175 ccohrs@warburg-research.com	Simon Stippig Real Estate, Telco	+49 40 309537-265 sstippig@warburg-research.com
Dr. Christian Ehmann	+49 40 309537-167	Cansu Tatar	+49 40 309537-248
BioTech, Life Science	cehmann@warburg-research.com	Cap. Goods, Engineering	ctatar@warburg-research.com
Felix Ellmann Software, IT	+49 40 309537-120 fellmann@warburg-research.com	Marc-René Tonn Automobiles, Car Suppliers	+49 40 309537-259 mtonn@warburg-research.com
Jörg Philipp Frey	+49 40 309537-258	Robert-Jan van der Horst	+49 40 309537-290
Retail, Consumer Goods Marius Fuhrberg	jfrey@warburg-research.com +49 40 309537-185	Technology Andreas Wolf	rvanderhorst@warburg-research.com +49 40 309537-140
Financial Services	mfuhrberg@warburg-research.com	Software, IT	awolf@warburg-research.com
Mustafa Hidir	+49 40 309537-230		
Automobiles, Car Suppliers	mhidir@warburg-research.com		
Thor Höfs Software, IT	+49 40 309537-255 thoefs@warburg-research.com		
Philipp Kaiser	+49 40 309537-260		
Real Estate, Construction	pkaiser@warburg-research.com		
INSTITUTIONAL EQUI	ITY SALES		
Marc Niemann	+49 40 3282-2660	Christopher Seedorf	+49 40 3282-2695
Head of Equity Sales, Germany Klaus Schilling	mniemann@mmwarburg.com +49 69 5050-7400	Switzerland	cseedorf@mmwarburg.com
Head of Equity Sales, Germany	kschilling@mmwarburg.com		
Tim Beckmann	+49 40 3282-2665		
United Kingdom	tbeckmann@mmwarburg.com		
Lea Bogdanova United Kingdom, Ireland	+49 69 5050-7411 lbogdanova@mmwarburg.com		
Jens Buchmüller	+49 69 5050-7415	Sophie Hauer	+49 69 5050-7417
Scandinavia, Austria	jbuchmueller@mmwarburg.com	Roadshow/Marketing	shauer@mmwarburg.com
Matthias Fritsch United Kingdom	+49 40 3282-2696 mfritsch@mmwarburg.com	Juliane Niemann Roadshow/Marketing	+49 40 3282-2694 jniemann@mmwarburg.com
Maximilian Martin	+49 69 5050-7413	Alicia Schmidt	+49 69 5050-7416
Austria, Poland	mmartin@mmwarburg.com	Roadshow/Marketing	Alicia.Schmidt@mmwarburg.com
SALES TRADING			
Oliver Merckel	+49 40 3282-2634	Marcel Magiera	+49 40 3282-2662
Head of Sales Trading Elyaz Dust	omerckel@mmwarburg.com +49 40 3282-2702	Sales Trading Bastian Quast	mmagiera@mmwarburg.com +49 40 3282-2701
Sales Trading	edust@mmwarburg.com	Sales Trading	bquast@mmwarburg.com
Michael Ilgenstein	+49 40 3282-2700	Jörg Treptow	+49 40 3282-2658
Sales Trading	milgenstein@mmwarburg.com	Sales Trading	jtreptow@mmwarburg.com
MACRO RESEARCH			
Carsten Klude Macro Research	+49 40 3282-2572 cklude@mmwarburg.com	Dr. Christian Jasperneite Investment Strategy	+49 40 3282-2439 cjasperneite@mmwarburg.com
Our research can be f	ound under:		
Warburg Research	research.mmwarburg.com/en/index.html	Refinitiv	www.refinitiv.com
Bloomberg	RESP MMWA GO	Capital IQ	www.capitaliq.com
FactSet	www.factset.com		
For access please conta	act:		
Andrea Schaper	+49 40 3282-2632	Kerstin Muthig	+49 40 3282-2703
Sales Assistance	aschaper@mmwarburg.com	Sales Assistance	kmuthig@mmwarburg.com
Calod / todiotal loc	aschaper@hilliwarburg.com	Calco / Colotalice	kindung@mmwarburg.com